ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. Leading healthcare companies have licensed rights to use ImmunoGen's technology to develop novel anticancer therapies, and Roche's marketed product, Kadcyla, utilizes ImmunoGen's ADC technology.
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
308 (est)
ImmunoGen was founded in 1981 and is headquartered in Waltham, US
Report incorrect company information

ImmunoGen Office Locations

ImmunoGen has offices in Brentwood, Waltham and Norwood
Waltham, US (HQ)
830 Winter St
Norwood, US
333 Providence Hwy
Show all (3)
Report incorrect company information

ImmunoGen Financials and Metrics

ImmunoGen Financials

ImmunoGen's revenue was reported to be $115.45 m in FY, 2017
USD

Revenue (FY, 2017)

115.4 m

Net income (FY, 2017)

(96 m)

EBIT (FY, 2017)

(59 m)

Market capitalization (23-Apr-2018)

991.8 m

Cash (31-Dec-2017)

267.1 m
ImmunoGen's current market capitalization is $991.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

59.9 m85.5 m60 m115.4 m

Revenue growth, %

43%(30%)

General and administrative expense

36.9 m33.9 m

R&D expense

148.1 m139.7 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2017Q2, 2017

Revenue

17.2 m30.1 m6.9 m13.2 m48.3 m11.4 m14.9 m18 m19.7 m7.7 m28.5 m39 m

General and administrative expense

6.5 m5.4 m6 m7.1 m6.9 m7 m8.3 m8.1 m11.2 m9.5 m8.1 m8.8 m

R&D expense

22 m20.9 m38.3 m28 m27.6 m25.7 m35.1 m38.2 m36.1 m32.9 m32.9 m35.3 m

Operating expense total

28.6 m26.3 m44.3 m35.1 m34.5 m32.7 m43.5 m46.3 m47.3 m46.5 m41.4 m44.2 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

142.3 m278.1 m245 m267.1 m

Accounts Receivable

1.9 m5.1 m883 k2.6 m

Inventories

3 m2.9 m907 k1 m

Current Assets

150.8 m292.2 m254.8 m276.3 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2017Q2, 2017

Cash

174.8 m178.1 m164.1 m121.8 m106.6 m111.8 m247.8 m212.3 m182.9 m196 m126.6 m150.3 m

Accounts Receivable

5.8 m3.8 m36 k1.8 m3.1 m754 k6.8 m803 k104 k316 k3.9 m1 m

Inventories

1.7 m3 m2.5 m2.1 m1.9 m2.7 m1.2 m1.5 m908 k2 m3.2 m3.5 m

Current Assets

187.7 m189.5 m172.3 m128.3 m114.4 m119.1 m262 m223.2 m193.3 m207.3 m142.1 m161.4 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(71.4 m)(60.7 m)(144.8 m)(96 m)

Depreciation and Amortization

4.6 m5.5 m5.3 m6 m

Inventories

(2.2 m)15 k2 m1.2 m

Accounts Payable

321 k3.3 m2.6 m771 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2017Q2, 2017

Net Income

(11.2 m)(7.4 m)(44.9 m)(22.3 m)(8.6 m)(30.3 m)(33.7 m)(67 m)(98.9 m)(44.7 m)(17.3 m)(26.2 m)

Depreciation and Amortization

1.2 m2.3 m3.4 m1.4 m2.8 m4.2 m1.1 m2.4 m3.8 m1.5 m1.5 m2.9 m

Inventories

(968 k)(2.3 m)(1.8 m)835 k1 m248 k1.7 m1.4 m2 m(1.1 m)(1 m)(1.3 m)

Accounts Payable

(1.4 m)(686 k)245 k138 k794 k1.5 m1.6 m3.2 m796 k(2.1 m)(2.5 m)(2.4 m)
USDY, 2017

Revenue/Employee

374.8 k
Show all financial metrics
Report incorrect company information